Abstract:4147 Background: Retrospective studies of phosphorylated STAT3 (pSTAT3, a regulator of gene expression) in cancer-lineage cells have suggested it is a biomarker of poor prognosis. We analyzed data from 3 phase 3 RCTs (BRIGHTER [T1; NCT02178956], CO.23 [T2; NCT01830621], CanStem111P [T3; NCT02993731]) to evaluate the prognostic impact of pSTAT3 on OS in GI cancer patients (pts). Methods: pSTAT3 was evaluated in archival tumor tissue from pts with gastric or gastroesophageal junction adenocarcinoma (T1), colorectal cancer (T2), or pancreatic cancer (T3) who received standard of care in the control arms (CTL) of their respective trials. pSTAT3 positive (+) or negative (−) status was determined by detecting pSTAT3 in both tumor and tumor microenvironment (TME) cells in a laboratory-developed immunohistochemistry (IHC) assay (T1; T2), later developed into the investigational pSTAT3 IHC D3A7 assay (Agilent Technologies, Inc.) (T3). The positivity cutoff requires a sample have both a TME score of 2 and ≥5% of tumor cells staining positively for pSTAT3. Pre-analytical variables (eg, specimen collection, handling, and processing), tumor indication, and slight differences in the assays used for each study may contribute to relative differences in evaluable rates between studies. In an exploratory analysis, OS was compared in pSTAT3+ vs pSTAT3− pts via an unstratified log-rank test. Results: In each study, intent-to-treat pts with evaluable pSTAT3 results were considered pSTAT3-evaluable. This abstract includes pSTAT3-evaluable pts randomized to the CTL arms (T1: n/N=248/357, 69.5%; T2: n/N=110/144, 76.4%; T3: n/N=243/569, 42.7%). Baseline characteristics are presented in the table. Median (m) OS was shorter in pts with pSTAT3+ tumors across all studies (T1 hazard ratio [HR]=1.32 [95% confidence interval (CI): 1.00, 1.74]; T2 HR=2.40 [1.50, 3.83]; T3 HR=1.08 [0.77, 1.50]). Conclusions: In pSTAT3-evaluable populations from 3 RCTs across GI cancers, CTL pts with pSTAT3+ (vs pSTAT3−) tumors had shorter mOS. These results suggest that pSTAT3 positivity may be a biomarker of poor clinical outcome. Clinical trial information: NCT02178956; NCT01830621; NCT02993731. [Table: see text]

Prognostic Role of Phospho-Stat3 in Patients with Cancers of the Digestive System: A Systematic Review and Meta-Analysis

Pan-cancer Analysis of STAT3 Indicates Its Potential Prognostic Value and Correlation with Immune Cell Infiltration in Prostate Cancer

Prognostic Role of Stat3 in Solid Tumors: A Systematic Review and Meta-Analysis

The Prognosis of Signal Transducer and Activator of Transcription 3 Expression on Breast Cancer Survival: a Meta-Analysis and Retrospective Study

A Meta-Analysis of STAT3 and Phospho-Stat3 Expression and Survival of Patients with Non-Small-cell Lung Cancer.

Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma

Data from Clinical Implications of Phosphorylated STAT3 Expression in <i>de Novo</i> Diffuse Large B-cell Lymphoma

Clinicopathological and Prognostic Role of STAT3/p-STAT3 in Breast Cancer Patients in China: A Meta-Analysis

Prognostic impact of pSTAT3 on overall survival (OS) in gastrointestinal (GI) cancers: Data from 3 phase 3, randomized controlled trials (RCTs).

P-STAT3 and IL-17 in Tumor Tissues Enhances the Prognostic Value of CEA and CA125 in Patients with Lung Adenocarcinoma

Prognostic and clinical significance of STAT3 and MMP9 in patients with gastric cancer: a meta-analysis of a Chinese cohort.

Correlation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysis

Correlation of pSTAT3 overexpression and prognosis in lung cancer patients: a meta-analysis

Activation of STAT3 in Human Gastric Cancer Cells Via Interleukin (Il)-6-type Cytokine Signaling Correlates with Clinical Implications

Prognostic Significance of Phosphorylated Signal Transducer and Activator of Transcription 3 and Suppressor of Cytokine Signaling 3 Expression in Hepatocellular Carcinoma

Phospho-Stat3 Expression and Correlation with VEGF, P53, and Bcl-2 in Gastric Carcinoma Using Tissue Microarray.

Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis.

Prognostic Significance of STAT3 Expression and Its Correlation with Chemoresistance of Non-Small Cell Lung Cancer Cells

[Constitutive Activation and Clinical Significance of Stat3 in Human Gastric Cancer Tissues and Cell Lines].

Phosphoserine Phosphatase As a Prognostic Biomarker in Patients with Gastric Cancer and Its Potential Association with Immune Cells

Mining the Prognostic Significance and Immune Infiltration of STAT Family Members in Human Breast Cancer by Bioinformatics Analysis